DOCSLIB.ORG

Study Protocol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

NCT02907177 Ponesimod / ACT-128800 Relapsing Multiple Sclerosis Protocol AC-058B302 POINT: POnesImod aNd Tecfidera Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) Study Phase: 3 EudraCT Number: 2012-000541-12 Status and version: Final Version 6 Date: 21 December 2017 Actelion document number D-17.622 (Doc No.): Confidentiality statement The information contained in this document, especially unpublished data, is the property of the sponsor of this study, Actelion Pharmaceuticals Ltd. It is therefore provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Actelion Pharmaceuticals Ltd, except to the extent necessary to obtain informed consent from those persons to whom the study treatment may be administered. TPL-000052_v10 Ponesimod / ACT-128800 EudraCT 2012-000541-12 Relapsing multiple sclerosis Doc No D-17.622 Protocol AC-058B302, POINT Confidential Version 6 21 December 2017, page 2/330 SPONSOR CONTACT DETAILS SPONSOR ACTELION Pharmaceuticals Ltd Gewerbestrasse 16 CH-4123 Allschwil Switzerland +41 61 565 65 65 Clinical Trial Physician Contact details of the Clinical Trial Physician can be found in the Investigator Site File MEDICAL HOTLINE Site-specific toll telephone numbers and toll-free Toll phone number: [number] numbers for the Medical Hotline can be found in the Investigator Site File ACTELION CONTRIBUTORS TO THE PROTOCOL Clinical Trial Scientist PPD , MSc Clinical Project Scientist PPD PhD Clinical Science Program Head PPD , MD, PhD Clinical Trial Statistician PPD . (FH) Clinical Project Statistician PPD , MSc Clinical Trial Physician Ewa Lindenstrøm, MD, PhD Clinical Trial Pharmacologist PPD Drug Safety Physician PPD , MD Ponesimod / ACT-128800 EudraCT 2012-000541-12 Relapsing multiple sclerosis Doc No D-17.622 Protocol AC-058B302, POINT Confidential Version 6 21 December 2017, page 3/330 CONTRACT RESEARCH ORGANIZATIONS INFORMATION CENTRAL LABORATORY Covance, Inc. 8211 SciCor Drive Indianapolis, IN USA 46214 Covance, Inc. 7 rue Marcinhes Geneva Meyrin Switzerland 1217 Covance, Inc. 1 International Business Park #01-01 The Synergy Singapore 609917 CENTRAL PK ANALYSIS PRA Health Sciences - Early Development Services LABORATORY Bioanalytical Laboratory Amerikaweg 18 9407 TK Assen, The Netherlands CENTRAL Almac Clinical Technologies RANDOMIZATION 25 Fretz Road Souderton PA 18964 USA CENTRAL MRI READING MIAC Corporation c/o University Hospital Basel Mittlere-Strasse 83 CH 4031 Basel, Switzerland CENTRAL ECGs READING eResearch Technology GmbH Sieboldstr. 3 97230 Estenfeld, Germany ELECTRONIC DIARY eResearch technology GmBH Sieboldstr. 3 97230 Estenfeld, Germany A list of site-specific contact details for Contract Research Organizations (CROs) can be found in the Investigator Site File. Ponesimod / ACT-128800 EudraCT 2012-000541-12 Relapsing multiple sclerosis Doc No D-17.622 Protocol AC-058B302, POINT Confidential Version 6 21 December 2017, page 4/330 SIGNATURE PAGE FOR ACTELION PHARMACEUTICALS LTD Hereinafter called Actelion Treatment name / number Ponesimod / ACT-128800 Indication Relapsing multiple sclerosis Protocol number, study acronym, study title AC-058B302, POINT, Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) I approve the design of this study. TITLE NAME DATE SIGNATURE PPD Clinical Trial Ewa Lindenstrøm, Physician MD, PhD P Clinica P PPD PPD Project D Statistician PPD ,PPD PPD Ponesimod / ACT-128800 EudraCT 2012-000541-12 Relapsing multiple sclerosis Doc No D-17.622 Protocol AC-058B302, POINT Confidential Version 6 21 December 2017, page 5/330 INVESTIGATOR SIGNATURE PAGE Treatment name / number Ponesimod / ACT-128800 Indication Relapsing multiple sclerosis Protocol number, study acronym, study title AC-058B302, POINT, Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) I agree to the terms and conditions relating to this study as defined in this protocol, the electronic Case Report Form (CRF), and any other protocol-related documents. I fully understand that any changes instituted by the investigator(s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study subjects (other than those procedures necessary for the wellbeing of the subjects). I agree to conduct this study in accordance with the Declaration of Helsinki principles, International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and applicable regulations and laws. I will obtain approval by an Institutional Review Board or Independent Ethics Committee (IRB/IEC) prior to study start and signed informed consent from all subjects included in this study. If an amendment to the protocol is necessary, I will obtain approval by an IRB/IEC and ensure approval by regulatory authorities (if applicable) have been obtained before the implementation of changes described in the amendment. I will allow direct access to source documents and study facilities to sponsor representative(s), particularly monitor(s) and auditor(s), and agree to inspection by regulatory authorities or IRB/IEC representative. I will ensure that the study treatment(s) supplied by the sponsor are being used only as described in this protocol. I will ensure that all subjects or legally designated representatives have understood the nature, objectives, benefits, implications, risks and inconveniences for participating in this study. During the conduct of the study, I will constantly monitor the risk/benefit balance for an individual subject. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact details and function in an electronic database for internal purposes and for submission to Health Authorities worldwide. Country Site Town Date Signature number Principal Investigator Ponesimod / ACT-128800 EudraCT 2012-000541-12 Relapsing multiple sclerosis Doc No D-17.622 Protocol AC-058B302, POINT Confidential Version 6 21 December 2017, page 6/330 TABLE OF CONTENTS ACTELION CONTRIBUTORS TO THE PROTOCOL.....................................................2 CONTRACT RESEARCH ORGANIZATIONS INFORMATION ...................................3 LIST OF ABBREVIATIONS AND ACRONYMS ..........................................................17 SUBSTANTIAL GLOBAL AMENDMENT 5.................................................................22 PROTOCOL SYNOPSIS AC-058B302............................................................................32 1 BACKGROUND.........................................................................................................60 1.1 Multiple sclerosis..........................................................................................60 1.1.1 Pathogenesis......................................................................................60 1.1.2 Clinical course ..................................................................................60 1.1.3 Epidemiology....................................................................................62 1.1.4 Treatment of MS...............................................................................62 1.1.4.1 Injectable disease-modifying therapies ...................................63 1.1.4.2 Orally administered disease-modifying therapies ...................63 1.1.4.3 Unmet need in relapsing multiple sclerosis.............................63 1.2 Sphingosine-1-phosphate receptors..............................................................64 1.3 Ponesimod ....................................................................................................65 1.3.1 Nonclinical studies............................................................................65 1.3.1.1 Efficacy of combined dimethyl fumarate and ponesimod in rats .......................................................................................66 1.3.1.2 Combination toxicity study of combined dimethyl fumarate and ponesimod in beagle dogs .................................67 1.3.2 Clinical studies..................................................................................67 1.3.2.1 Clinical pharmacology ............................................................68 1.3.2.2 Pharmacodynamics in humans ................................................68 1.3.2.3 Efficacy in humans..................................................................69 1.3.2.4 Safety and tolerability .............................................................70 1.3.3 Background treatment.......................................................................71 1.4 Purpose and rationale of the study................................................................71 1.5 Summary of known and potential risks and benefits....................................72 2 STUDY OBJECTIVES ...............................................................................................75
Recommended publications
  • Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes

    Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes

    Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes Sylvaine You1,2, Luca Piali3, Chantal Kuhn1,2, Beat Steiner3, Virginia Sauvaget1,2, Fabrice Valette1,2, Martine Clozel3, Jean-Franc¸ois Bach1,2, Lucienne Chatenoud1,2* 1 Universite´ Paris Descartes, Sorbonne Paris Cite´, Paris, France, 2 Institut National de la Sante´ et de la Recherche Me´dicale, Unite´ 1013, Paris, France, 3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland Abstract In the present study, we investigated the therapeutic potential of a selective S1P1 receptor modulator, ponesimod, to protect and reverse autoimmune diabetes in non-obese diabetic (NOD) mice. Ponesimod was administered orally to NOD mice starting at 6, 10, 13 and 16 weeks of age up to 35 weeks of age or to NOD mice showing recent onset diabetes. Peripheral blood and spleen B and T cell counts were significantly reduced after ponesimod administration. In pancreatic lymph nodes, B lymphocytes were increased and expressed a transitional 1-like phenotype. Chronic oral ponesimod treatment efficiently prevented autoimmune diabetes in 6, 10 and 16 week-old pre-diabetic NOD mice. Treatment withdrawal led to synchronized disease relapse. Ponesimod did not inhibit the differentiation of autoreactive T cells as assessed by adoptive transfer of lymphocytes from treated disease-free NOD mice. In addition, it did not affect the migration, proliferation and activation of transgenic BDC2.5 cells into the target tissue. However, ponesimod inhibited spreading of the T cell responses to islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Treatment of diabetic NOD mice with ponesimod induced disease remission. However, here again, upon treatment cessation, the disease rapidly recurred.
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity

    Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity

    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort Kallweit, U ; Jelcic, I ; Braun, N ; Fischer, H ; Zörner, B ; Schreiner, B ; Sokolov, A A ; Martin, R ; Weller, M ; Linnebank, M Abstract: OBJECTIVES: Therapy for relapsing-remitting multiple sclerosis with natalizumab (Tysabri; Biogen Idec) has been shown to be effective in the reduction of the clinical relapse rate and disability progression. However, real-life longitudinal data, including years before baseline, are rare. METHODS: An observational single-center study was carried out. We analyzed data from 64 consecutive patients with multiple sclerosis. RESULTS: After 1 year of treatment (n = 64), score on the Expanded Disability Status Scale (EDSS) decreased by 0.47 points (P = 0.047) and the annualized relapse rate (ARR) decreased by 82% (P < 0.001). After 2 years (n = 41), EDSS score was still reduced by 0.28 (not significant) and ARR was reduced by 69% (P < 0.001). After 3 years (n = 23), EDSS score was reduced by 0.26 (not significant), and ARR was reduced by 77% (P < 0.001). Reduction of EDSS score andARRdid not depend on baseline ARR (1-2 vs >2) or EDSS score and was not biased by exceptional high disease activity or relapses around baseline. CONCLUSIONS: These real-life data reinforce that natalizumab is effective over years, reduces ARR, and stabilizes EDSS score independent of baseline ARR, baseline EDSS score, or baseline treatment.
  • Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: a Review Article

    Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: a Review Article

    biomedicines Review Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article Stanley Cohan, Elisabeth Lucassen, Kyle Smoot, Justine Brink and Chiayi Chen * Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Providence St, Vincent Medical Center, Portland, OR 97225, USA; [email protected] (S.C.); [email protected] (E.L.); [email protected] (K.S.); [email protected] (J.B.) * Correspondence: [email protected]; Tel.: +1-503-216-1012 Received: 27 May 2020; Accepted: 15 July 2020; Published: 18 July 2020 Abstract: Sphingosine-1-phosphate (S1P), via its G-protein-coupled receptors, is a signaling molecule with important regulatory properties on numerous, widely varied cell types. Five S1P receptors (S1PR1-5) have been identified, each with effects determined by their unique G-protein-driven downstream pathways. The discovery that lymphocyte egress from peripheral lymphoid organs is promoted by S1P via S1PR-1 stimulation led to the development of pharmacological agents which are S1PR antagonists. These agents promote lymphocyte sequestration and reduce lymphocyte-driven inflammatory damage of the central nervous system (CNS) in animal models, encouraging their examination of efficacy in the treatment of multiple sclerosis (MS). Preclinical research has also demonstrated direct protective effects of S1PR antagonists within the CNS, by modulation of S1PRs, particularly S1PR-1 and S1PR-5, and possibly S1PR-2, independent of effects upon lymphocytes. Three of these agents, fingolimod, siponimod and ozanimod have been approved, and ponesimod has been submitted for regulatory approval. In patients with MS, these agents reduce relapse risk, sustained disability progression, magnetic resonance imaging markers of disease activity, and whole brain and/or cortical and deep gray matter atrophy.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Fingolimod (Gilenya)

    Fingolimod (Gilenya)

    Clinical Policy: Fingolimod (Gilenya) Reference Number: HIM.PA.SP10 Effective Date: 05/17 Coding Implications Last Review Date: Revision Log Line of Business: Health Insurance Marketplace See Important Reminder at the end of this policy for important regulatory and legal information. Description Fingolimod (Gilenya®) is a sphingosine 1-phosphate receptor modulator. FDA approved indication Gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. Policy/Criteria Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria I. Initial Approval Criteria A. Multiple Sclerosis (must meet all): 1. Diagnosis of relapsing MS established by magnetic resonance imaging (MRI); 2. Prescribed by or in consultation with a neurologist; 3. Member will not use other disease modifying therapies for MS concurrently; 4. Dose does not exceed 0.5 mg per day (1 capsule per day). Approval duration: 6 months B. Other diagnoses/indications 1. Refer to HIM.PHAR.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). II. Continued Therapy A. Multiple Sclerosis (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2. Documentation of positive response to therapy (e.g., improved or maintained disease control evidenced by increase in Expanded Disability Status Scale (EDSS) or reduction in relapses or MRI lesions); 3. Member is not using other disease modifying therapies for MS concurrently; 4. If request is for a dose increase, new dose does not exceed 0.5 mg per day (1 capsule per day).
  • Oral MS Disease-Modifying Therapies C21142-A

    Oral MS Disease-Modifying Therapies C21142-A

    Drug and Biologic Coverage Criteria Effective Date: 05/01/2019 Last P&T Approval/Version: 07/28/2021 Next Review Due By: 08/2022 Policy Number: C21142-A Oral MS Disease-Modifying Therapies PRODUCTS AFFECTED Mayzent (siponimod), Aubagio (teriflunomide), Gilenya (fingolimod), Mavenclad (cladribine), Tecfidera (dimethyl fumarate), Vumerity (diroximel fumarate), Bafiertam (monomethyl fumarate),dimethyl fumarate, Zeposia (ozanimod), Ponvory (ponesimod) COVERAGE POLICY Coverage for services, procedures, medical devices, and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines Documentation Requirements: Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive DIAGNOSIS: Multiple Sclerosis REQUIRED MEDICAL INFORMATION: A.
  • Ozanimod for Treating Relapsing–Remitting Multiple Sclerosis [ID1294] ERG Report Copyright 2021 Queen's Printer and Controller of HMSO

    Ozanimod for Treating Relapsing–Remitting Multiple Sclerosis [ID1294] ERG Report Copyright 2021 Queen's Printer and Controller of HMSO

    Confidential until published Fprofile REPORT REPORT ERG STA ERG STA Ozanimod for treating relapsing– remitting multiple sclerosis Confidential until published This report was commissioned by the NIHR HTA Programme as project number NIHR 17/156/08 Completed 21 January 2020 Updated 2 September 2020 CONFIDENTIAL DATA HAS BEEN REDACTED Copyright belongs to the Liverpool Reviews and Implementation Group Ozanimod for treating relapsing–remitting multiple sclerosis [ID1294] ERG Report Copyright 2021 Queen's Printer and Controller of HMSO. All rights reserved. Page 1 of 98 Confidential until published Title: Ozanimod for treating relapsing–remitting multiple sclerosis [ID1294] Produced by: Liverpool Reviews & Implementation Group (LRiG) Authors: Nigel Fleeman, Senior Research Fellow (Clinical Effectiveness), LRiG, University of Liverpool James Mahon, Director, Coldingham Analytical Services, Berwickshire Sarah Nevitt, Research Associate (Medical Statistician), LRiG, University of Liverpool Sophie Beale, Research Associate, LRiG, University of Liverpool Angela Boland, Director, LRiG, University of Liverpool Rui Duarte, Deputy Director, LRiG, University of Liverpool Rachel Houten, Health Economic Modeller, LRiG, University of Liverpool Joanne McEntee, Senior Medicines Information Pharmacist, North West Medicines Information Centre, Liverpool Ian Pomeroy, Honorary Lecturer, School of Medicine, University of Liverpool and Consultant Neurologist, The Walton Centre NHS Foundation Trust, Liverpool and Warrington Correspondence to: Nigel Fleeman, Research Fellow, Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, The Quadrangle, Brownlow Hill, Liverpool L69 3GB Date completed: 21 January 2020 (Updated 2 September 2020) Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 17/156/08 Acknowledgements: The authors would like to thank Siân Price, Consultant Neurologist at Sheffield Teaching Hospitals NHS Foundation Trust who provided feedback on a draft version of the report.
  • Multiple Sclerosis Research: Diagnostics, Disease-Modifying

    Multiple Sclerosis Research: Diagnostics, Disease-Modifying

    S14 Journal of Neuroscience Nursing Multiple Sclerosis Research: Diagnostics, Disease-Modifying Treatments, and Emerging Therapies Kathleen Costello ABSTRACT Multiple sclerosis (MS) is a complex disease that affects the central nervous system. It is believed to be an immune mediated disease, and although the etiology remains unknown, it is believed to occur from a combination of genetic risk factors and environmental risk factors. There is no single diagnostic test for MS, and diagnostic criteria have been developed to aid the provider in making an accurate and timely diagnosis. Once a diagnosis of MS is made, treatments directed toward the inflammatory immune response should be initiated. Currently, there are 10 treatments for MS: four interferon beta products; one glatiramer acetate; one monoclonal antibodyVnatalizumab; three oral treatmentsVfingolimod, teriflunomide, and dimethyl fumarate; and one immunosuppressant agentVmitoxantrone. Each of these agents has a different administration and different risks and side effects. Numerous agents are in late stage development, and it is possible that several more agents, all with different mechanisms of action, will become available over the next several years. Keywords: alemtuzumab, daclizumab, dimethyl fumarate, disease modifying treatment, fingolimod, glatiramer acetate, interferon beta, laquinimod, MCDONALD Criteria, multiple sclerosis, natalizumab, teriflunomide ultiple sclerosis (MS) is a chronic disease of the disease from onset, known as primary progres- of the central nervous system
  • Risk Assessment and Risk Mitigation Review(S)

    Risk Assessment and Risk Mitigation Review(S)

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213498Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NOA Application Number 213498 POU FA Goal Date March 18, 2021 OSE RCM # 2020-534 Reviewer Name(s) Carlisha Gentles, PharmD, BCPS Team Leader Jacqueline Sheppard, PharmD Deputy Director Doris Auth, PharmD Review Completion Date March 2, 2021 Subject Eva luation of Need for a REMS Established Name Ponesimod Trade Name Ponvory Name of Applicant Janssen Pharmaceuticals Inc Therapeutic Class Sphingosine 1-phosphate (SlP) receptor modulator Formulation(s) Film-coated tablets: 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 20 mg Dosing Regimen Treatment init iation with a 14-day titration (see table), followed by a maintenance regimen of 20 mg orally once daily Treatment init iation titration: Titration Day Daily Dose Day 1 a nd 2 2mg Day 3 a nd 4 3mg Day 5 a nd 6 4mg Day7 Smg Dav8 6mg Day9 7mg Day10 8mg Day ll 9mg Day 12, 13, and 14 10mg 1 Reference ID 4755518 Table of Contents EXECUTIVE SUMMARY ......................................................................................................................................................... 3 1 Introduction ....................................................................................................................................................................
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION

    COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION

    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.